Progress in the development of matrix metalloproteinase inhibitors

被引:88
|
作者
Tu, GuoGang [1 ,2 ]
Xu, WenFang
Huang, HuiMing [2 ]
Li, ShaoHua [2 ]
机构
[1] Shandong Univ, Dept Med Chem, Sch Pharmaceut Sci, Jinan 250012, Peoples R China
[2] NanChang Univ, Coll Med, Dept Pharm, Nanchang 330006, Peoples R China
关键词
matrix metalloproteinases; MMP inhibitors; Zinc-binding groups; cancer; computer-aided drug design; angiogenesis; metastasis; proteases;
D O I
10.2174/092986708784567680
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Matrix metalloproteinases ( MMPs) are a family of zinc-dependent proteinases involved in the degradation and remodeling of extracellular matrix proteins that are associated with the tumorigenic process. MMPs promote tumor invasion and metastasis, regulating host defense mechanisms and normal cell function. Thus, MMP inhibitors (MMPIs) are expected to be useful for the treatment of diseases such as cancer, osteoarthritis, and rheumatoid arthritis. A vast number of MMPIs have been developed in recent years. With the failure of these inhibitors in clinical trials, more efforts have been directed to the design of specific inhibitors with different Zn-binding groups. This review summarizes the current status of MMPIs, the design of small molecular weight MMPIs, a brief description of available three-dimensional MMP structures, a review of the proposed therapeutic utility of MMPIs, and a clinical update of compounds that have entered clinical trials in humans.
引用
收藏
页码:1388 / 1395
页数:8
相关论文
共 50 条
  • [31] Matrix metalloproteinase inhibitors (MMPIs) as attractive therapeutic targets: Recent progress and current challenges
    Shi, Ying
    Ma, Xiaochuan
    Fang, Ge
    Tian, Xin
    Ge, Cuicui
    NANOIMPACT, 2021, 21
  • [32] Development of novel matrix metalloproteinase inhibitors and their effects on isolated stunned hearts
    Romero-Perez, D.
    Puerta, D.
    Lewis, J.
    Mongan, J.
    McCammon, A.
    Villarreal, F.
    Cohen, S.
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2006, 40 (06) : 896 - 896
  • [33] Matrix Metalloproteinase Inhibitors: Applications in Oncology
    Desmond Yip
    Athar Ahmad
    Christos S. Karapetis
    Carolyn A. Hawkins
    Peter G. Harper
    Investigational New Drugs, 1999, 17 : 387 - 399
  • [34] Matrix metalloproteinase inhibitors: Applications in oncology
    Yip, D
    Ahmad, A
    Karapetis, CS
    Hawkins, CA
    Harper, PG
    INVESTIGATIONAL NEW DRUGS, 1999, 17 (04) : 387 - 399
  • [35] Ongoing trials with matrix metalloproteinase inhibitors
    Brown, PD
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (09) : 2167 - 2177
  • [36] Matrix metalloproteinase inhibitors as anticancer therapeutics
    Mannello, F
    Tonti, G
    Papa, S
    CURRENT CANCER DRUG TARGETS, 2005, 5 (04) : 285 - 298
  • [37] Clinical studies with matrix metalloproteinase inhibitors
    Brown, PD
    APMIS, 1999, 107 (01) : 174 - 180
  • [38] Matrix metalloproteinase inhibitors as anticancer agents
    Konstantinopoulos, Panagiotis A.
    Karamouzis, Michalis V.
    Papatsoris, Athanasios G.
    Papavassiliou, Athanasios G.
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2008, 40 (6-7): : 1156 - 1168
  • [39] Matrix metalloproteinase inhibitors for treatment of cancer
    Skiles, JW
    Monovich, LG
    Jeng, AY
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 35, 2000, 35 : 167 - 176
  • [40] Matrix metalloproteinase inhibitors: Current status
    Morphy, JR
    Millican, TA
    Porter, JR
    CURRENT MEDICINAL CHEMISTRY, 1995, 2 (03) : 743 - 762